Healthcare Industry News: Valeritas
News Release - July 25, 2011
TARIS Appoints Christopher Searcy as the Company’s Chief Business OfficerLEXINGTON, Mass.--(Healthcare Sales & Marketing Network)-- TARIS Biomedical®, a specialty pharmaceutical company pioneering the development of innovative, targeted therapies using drug delivery to treat bladder diseases, announced today that Dr. Christopher Searcy has joined the company as its Chief Business Officer and Senior VP of Corporate Development. In this role he will have global responsibility for the business strategy for TARIS including corporate partnerships and other strategic alliances involving the company’s products and technologies.
“We are very pleased to welcome Chris to the TARIS team,” said Sarma Duddu, PhD, President and CEO, TARIS Biomedical®. “With more than twenty-five years of corporate and business development experience in drug delivery based pharmaceutical and biotechnology companies, Chris will be a great asset to TARIS as we continue to evolve into a late-stage specialty pharmaceutical company in the genitourinary therapeutic segment.”
“I am excited to join TARIS and look forward to working with the team to leverage its industry-leading drug-device convergence platform. TARIS is well positioned to generate significant value and emerge as a leader in the field of sustained therapeutic delivery to the bladder,” said Christopher Searcy, Chief Business Officer at TARIS.
Prior to joining TARIS, Dr. Searcy served as Senior Vice President of Corporate and Business Development at Valeritas Inc. in which he supported the registration and preparation for launch of its first product and expanded the business by leveraging the company’s technology platforms for additional applications. Prior to Valeritas, Dr Searcy was Vice President of Corporate Development for Inhale/Nektar Therapeutics (NASDAQ:NKTR ), Vice President of Business Development for Galagen Inc. and Director of Licensing and Development for Pfizer International and Pfizer Inc. Dr. Searcy received his MBA from the Wharton School at the University of Pennsylvania and his Doctor of Pharmacy from the University of Minnesota.
About Bladder Disease
Bladder diseases, which are difficult to treat with systemic therapies, affect 60 million people in the U.S. alone. These diseases include interstitial cystitis (IC)/painful bladder syndrome (PBS), bladder cancer, overactive bladder, urinary tract infections and chronic pelvic pain syndrome.
About TARIS Biomedical®
TARIS Biomedical® is a product-focused drug delivery company treating genitourinary conditions, with deep domain expertise in the sustained local delivery of therapeutics to target tissues. TARIS is focused on developing a pipeline of novel therapeutics designed to leverage common, minimally invasive urologic procedures. The TARIS core technology and development efforts are being applied to diseases with high unmet medical need in which current therapies or systemic treatments have failed. TARIS is initially focused on treating disorders of the genitourinary system, specifically the treatment of bladder diseases. Its most advanced product candidate LiRIS® is currently in clinical development for the treatment of interstitial cystitis (IC). Based in Lexington, MA, TARIS Biomedical’s technology was developed by internationally renowned scientists from the Massachusetts Institute of Technology, Robert Langer ScD and Michael Cima PhD, and is backed by leading venture capital firms Flagship Ventures, Flybridge Capital Partners, Polaris Venture Partners and Third Rock Ventures. For more information, visit www.tarisbiomedical.com .
Source: TARIS Biomedical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.